Abstract
Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have